Concepts/ Anatomical substrates/ Physiology and pathophysiology/ Reading between the lines/ The why and why not/ Looking from another angle/ Molecular basis/ Ideas
Tuesday, September 13, 2011
Rasagiline
Selective MAO-B irreversible inhibitor.
Adv over Selegeline - OD dose, milder S/E, non-amphetamine metabolites
ADAGIO trial suggested neuroprotective at 1mg, but findings did not hold at 2mg/day.
No comments:
Post a Comment